Acadia Pharmaceuticals (ACAD) Cash & Equivalents (2010 - 2026)

Acadia Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $282.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 29.64% year-over-year to $282.2 million; the TTM figure through Mar 2026 stood at $282.2 million (up 29.64% YoY), while the FY2025 annual figure was $177.7 million, down 44.4% from the prior year.
• Cash & Equivalents was $282.2 million for Q1 2026 at Acadia Pharmaceuticals, up from $177.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $319.6 million in Q4 2024 to a low of $98.2 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $196.8 million across 5 years, with a median of $188.7 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents plunged 47.62% in 2022, then jumped 69.4% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $114.8 million in 2022, then surged by 64.27% to $188.7 million in 2023, then surged by 69.4% to $319.6 million in 2024, then slumped by 44.4% to $177.7 million in 2025, then jumped by 58.82% to $282.2 million in 2026.
• The last three Cash & Equivalents figures came in at $282.2 million (Q1 2026), $177.7 million (Q4 2025), and $258.0 million (Q3 2025), per Business Quant data.